

**MariMed Reports Third Quarter 2022 Earnings**

**NORWOOD, MA, November 7, 2022** - [MariMed, Inc.](http://www.marimedinc.com/) (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the third quarter ended September 30, 2022.

“I am pleased to report we grew revenue both year-over-year and sequentially, despite continued headwinds facing the entire industry,” said Bob Fireman, Chief Executive Officer. “MariMed continues to outperform these industry dynamics on the strength of our outstanding retail and wholesale operations, high quality and innovative product mix, and exceptional customer service.”

**Financial Highlights1**

The following table summarizes the consolidated financial highlights for the three months ended September 30, 2022 and 2021 (in millions, except percentage amounts):

|  |  |
| --- | --- |
|  | **Three months ended** **September 30,** |
|  | **2022** |  | **2021** |
| Revenue | $ 33.9  |  | $ 33.2  |
| Gross margin |  48%  |  |  55%  |
| GAAP Net income | $ 2.7  |  | $ 2.1  |
| Non-GAAP Adjusted EBITDA | $ 8.6  |  | $ 12.6  |
| Non-GAAP Adjusted EBITDA margin |  25 % |  |  38 % |

1 See the reconciliations of non-GAAP financial measures to the most directly comparable GAAP measures and additional information about non-GAAP measures in the section entitled “Discussion of Non-GAAP Financial Measures” in the attached schedules.

**CONFERENCE CALL**

MariMed management will host a conference call on Tuesday, November 8, 2022, to discuss these results at 8:00 a.m. Eastern time. The conference call may be accessed through MariMed’s Investor Relations website by clicking the following link: [MariMed Q322 Earnings Webcast](https://app.webinar.net/oXWd5Zn5r68).

**THIRD QUARTER OPERATIONAL HIGHLIGHTS**

During the third quarter, the Company announced the following facets of its strategic growth plan, including:

* **July 18**: The approval of its expanded state-of-the-art kitchen in Maryland. The nearly ten-fold expansion allows the Company to produce all its award-winning branded products including *Betty’s Eddies* fruit chews, *Bubby’s Baked* baked goods*, K Fusion* chewable tablets, and *Vibations* *High + Energy* powdered drink mixes. The Company also introduced a line of gummies in the Maryland medical cannabis market, under the *In-House* brand.
* **August 4**: The launch of its new *Betty’s Eddies* ice cream in partnership with Boston-based *Emack & Bolio’s®* ice cream company. *Betty’s Eddies* ice cream is currently available in select cannabis dispensaries in Massachusetts.
* **August 8**: The acquisition of a conditional dispensary license in central eastern Illinois close to the Indiana border. Once open, it will mark the fifth *Thrive* branded dispensary the Company owns and operates in Illinois. MariMed currently owns and operates four adult-use dispensaries in Anna, Harrisburg, Metropolis, and Mt. Vernon.
* **August 30**: The launch of its *Nature's Heritage* "LIVE Flower," the freshest cannabis available. The unparalleled freshness is made possible through MariMed's proprietary FreshCure curing process, which delivers buds that are bigger and brighter than conventional flower, bursting with more vibrant colors and stronger aromas while delivering a smoother smoke.
* **September 12**: The agreement to develop and manage a state-of-the-art production kitchen to manufacture and wholesale its award winning branded products in Missouri. Voters are expected to approve an adult use measure on the ballot this fall, and the Company expects its branded products will be available on the wholesale market before adult-use sales commence.
* **September 13**: The agreement with 42 Degrees, a Michigan licensed cannabis producer and distributor, to manufacture and distribute MariMed’s award-winning brands and products throughout the state. 42 Degrees currently wholesales products into 340 dispensaries, representing approximately 75 percent of the operating dispensaries in Michigan.

**OTHER BUSINESS DEVELOPMENTS**

Subsequent to the end of the third quarter, the Company announced the following business developments:

* **October 5**: The opening of its first medical dispensary in Annapolis, Maryland, marking the beginning of the Company's fully vertical operations in that state. The *Panacea Wellness* dispensary is the eighth retail location across four states that MariMed either owns or manages. MariMed hosted a grand opening ceremony with several local, county, and state dignitaries in attendance to celebrate commencement of operations. Voters are expected to approve an adult use measure on the ballot this fall and MariMed expects to build out its footprint in Maryland to include the maximum allowable four dispensaries over time.
* **October 25**: The evolution of its award-winning and top-selling *Betty's Eddies* fruit chews line to address consumer demand for cannabis edibles that meet specific needs. Each new or improved chew has been custom formulated to help aid sleep, relaxation, pain relief, heightened libido, and more.

"We remain bullish for continued revenue and earnings growth,” said Jon Levine, President. “Fueling our confidence are several new and expanded assets in our existing markets that will come online in 2023. Additionally, we look forward to our entry next year into additional high-growth cannabis markets, including Ohio, Missouri, and Michigan.”

**2022 FINANCIAL GUIDANCE**

MariMed remains committed to its proven strategic growth plan and continues to operate some of the best cannabis facilities with some of the highest margins and returns in the cannabis industry. Due to continued regulatory delays with opening dispensaries, the Company's guidance for full year 2022 has been revised and is as follows:

* Revenue of $132 million to $135 million.
* Gross margin of 48% to 49%.
* Non-GAAP Adjusted EBITDA of $32 million to $35 million.
* Capital expenditures of $16 million to $17 million.

“Our financial results remain some of the best in the industry, as we have improved gross margins and delivered positive adjusted EBITDA for the eleventh consecutive quarter,” said Susan Villare, Chief Financial Officer. “Our ability to generate positive cash flow from operations in this challenging macro environment is a testament to the outstanding asset base that MariMed has developed and maintained.”

**DISCUSSION OF NON-GAAP FINANCIAL MEASURES**

The Company has provided in this release several non-GAAP financial measures: Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA and non-GAAP Adjusted EBITDA margin, as a supplement to Revenue, Gross margin, and other financial measures prepared in accordance with GAAP.

Management believes these non-GAAP financial measures are useful in reviewing and assessing the performance of the Company, as they provide meaningful operating results by excluding the effects of expenses that are not reflective of its operating business performance. In addition, the Company’s management uses these non-GAAP financial measures to understand and compare operating results across accounting periods and for financial and operational decision-making. The presentation of these non-GAAP measures is not intended to be considered in isolation or as a substitute for the financial information prepared in accordance with GAAP.

Management believes that investors and analysts benefit from considering non-GAAP financial measures in assessing the Company’s financial results and its ongoing business, as it allows for meaningful comparisons and analysis of trends in the business. In particular, non-GAAP adjusted EBITDA is used by many investors and analysts themselves, along with other metrics, to compare financial results across accounting periods and to those of peer companies.

As there are no standardized methods of calculating non-GAAP financial measures, the Company’s calculations may differ from those used by analysts, investors and other companies, even those within the cannabis industry, and therefore may not be directly comparable to similarly titled measures used by others.

Management defines non-GAAP Adjusted EBITDA as net income, determined in accordance with GAAP, excluding the following items:

* interest income and interest expense;
* income taxes;
* depreciation of fixed assets;
* amortization of acquired intangible assets;
* Impairment or write-downs of intangible assets;
* stock-based compensation;
* legal settlements;
* acquisition-related and other;
* other income and other expense;
* and discontinued operations.

For further information, please refer to the Company’s Quarterly Report on Form 10-Q for the three month period ended September 30, 2022 available on [MariMed's Investor Relations](https://ir.marimedinc.com/) website, on the SEC’s [Edgar](https://www.sec.gov/edgar/search/#/dateRange=all&ciks=0001522767&entityName=MARIMED%2520INC.%2520(MRMD)%2520(CIK%25200001522767)) website in the U.S., or on the Canadian securities regulatory authorities’ [SEDAR](https://www.sedar.com/DisplayProfile.do?lang=EN&issuerType=03&issuerNo=00054777) website in Canada.

**ABOUT MARIMED**

MariMed Inc., a multi-state cannabis operator, is dedicated to improving lives every day through its high-quality products, its actions, and its values. The Company develops, owns, and manages seed to sale state-licensed cannabis facilities, which are models of excellence in horticultural principles, cannabis cultivation, cannabis-infused products, and dispensary operations. MariMed has an experienced management team that has produced consistent growth and success for the Company and its managed business units. Proprietary formulations created by the Company’s technicians are embedded in its top-selling and award-winning products and brands, including *Betty’s Eddies, Nature’s Heritage, Bubby’s Baked, K Fusion, Kalm Fusion*, and *Vibations: High + Energy*. For additional information, visit [www.marimedinc.com](http://www.marimedinc.com).

**IMPORTANT CAUTION REGARDING FORWARD-LOOKING STATEMENTS:**

This release contains certain forward-looking statements and information relating to MariMed Inc. that are based on the beliefs of MariMed Inc.’s management, as well as assumptions made by and information currently available to the Company. Such statements reflect the current view of the Company with respect to future events, including consummation of pending transactions, launch of new products, expanded distribution of existing products, obtaining new licenses, estimates and projections of revenue, EBITDA and Adjusted EBITDA and other information about its business, business prospects and strategic growth plan, which are based on certain assumptions of its management, including those described in this release. These statements are not a guarantee of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company’s services and products, changes in the law and its enforcement, and changes in the economic environment. Additional risk factors are included in the Company’s public filings with the Securities and Exchange Commission. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as “hoped,” “anticipated,” “believed,” “planned, “estimated,” “preparing,” “potential,” “expected,” “looks” or words of a similar nature. The Company does not intend to update these forward-looking statements. None of the content of any of the websites referred to herein (even if a link is provided for your convenience) is incorporated into this release and the Company assumes no responsibility for any of such content.

All trademarks and service marks are the property of their respective owners.

**For More Information Contact:**

**Investor Relations:**

Steve West, Vice President, Investor Relations

Email: ir@marimedinc.com

Phone: (781) 277-0007

**Media Contact:**

Trailblaze PR

Email: marimed@trailblaze.co

**Company Contact:**

Howard Schacter, Chief Communications Officer

Email: hschacter@marimedinc.com

Phone: (781) 277-0007

**# # #**

MariMed Inc.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

|  |  |  |  |
| --- | --- | --- | --- |
|  | September 30,2022 |  | December 31,2021 |
| Assets |   |  |   |
| Current assets: |   |  |   |
| Cash and cash equivalents | $ 11,113  |  | $ 29,683  |
| Accounts receivable, net |  6,560  |  |  1,666  |
| Deferred rents receivable |  725  |  |  1,678  |
| Notes receivable, current portion |  134  |  |  127  |
| Inventory |  18,309  |  |  9,768  |
| Investments, current |  274  |  |  251  |
| Other current assets |  3,768  |  |  1,440  |
| Total current assets |  40,883  |  |  44,613  |
| Property and equipment, net |  70,396  |  |  62,150  |
| Intangible assets, net |  9,469  |  |  162  |
| Goodwill |  8,079  |  |  2,068  |
| Notes receivable, net of current |  9,160  |  |  8,987  |
| Operating lease right-of-use assets |  4,954  |  |  5,081  |
| Finance lease right-of-use assets |  747  |  |  46  |
| Other assets |  1,010  |  |  98  |
| Total assets | $ 144,698  |  | $ 123,205  |
|   |   |  |   |
| Liabilities, mezzanine equity and stockholders’ equity |  |  |  |
| Current liabilities: |  |  |  |
| Mortgages and notes payable, current portion | $ 2,825  |  | $ 1,410  |
| Accounts payable |  7,973  |  |  5,099  |
| Accrued expenses and other |  3,265  |  |  3,149  |
| Income taxes payable |  11,663  |  |  16,467  |
| Operating lease liabilities, current portion |  1,284  |  |  1,071  |
| Finance lease liabilities, current portion |  241  |  |  27  |
| Total current liabilities |  27,251  |  |  27,223  |
| Mortgages and notes payable, net of current |  23,048  |  |  17,262  |
| Operating lease liabilities, net of current |  4,214  |  |  4,574  |
| Finance lease liabilities, net of current |  483  |  |  22  |
| Other liabilities |  100  |  |  100  |
| Total liabilities |  55,096  |  |  49,181  |
|  |   |  |   |
| Commitments and contingencies |  |  |  |
|  |   |  |   |
| Mezzanine equity: |   |  |   |
| Series B convertible preferred stock |  14,725  |  |  14,725  |
| Series C convertible preferred stock |  23,000  |  |  23,000  |
| Total mezzanine equity |  37,725  |  |  37,725  |
|  |   |  |   |
| Stockholders’ equity |   |  |   |
| Common stock |  339  |  |  334  |
| Common stock subscribed but not issued |  41  |  |  —  |
| Additional paid-in capital |  141,652  |  |  134,920  |
| Accumulated deficit |  (88,675) |  |  (97,392) |
| Noncontrolling interests |  (1,480) |  |  (1,563) |
| Total stockholders’ equity |  51,877  |  |  36,299  |
| Total liabilities, mezzanine equity and stockholders’ equity | $ 144,698  |  | $ 123,205  |

MariMed Inc.

Condensed Consolidated Statements of Operations

(in thousands, except percentages and per share amounts)

(unaudited)

|  |  |  |  |
| --- | --- | --- | --- |
|  | Three months ended  |  | Nine months ended |
|  | September 30, |  | September 30, |
|  | 2022 |  | 2021 |  | 2022 |  | 2021 |
|  |  |  |  |  |  |  |  |
| Revenue | $ 33,912  |  | $ 33,208  |  | $ 98,180  |  | $ 90,420  |
| Cost of revenue |  17,748  |  |  15,027  |  |  50,035  |  |  39,647  |
| Gross profit |  16,164  |  |  18,181  |  |  48,145  |  |  50,773  |
|   |   |  |   |  |   |  |   |
| Gross margin |  47.7%  |  |  54.7%  |  |  49.0%  |  |  56.2%  |
|  |  |  |  |  |  |  |  |
| Operating expenses: |  |  |  |  |  |  |  |
| Personnel |  3,746  |  |  1,481  |  |  10,170  |  |  5,266  |
| Marketing and promotion |  1,402  |  |  563  |  |  2,854  |  |  1,058  |
| General and administrative |  5,097  |  |  9,481  |  |  16,890  |  |  16,934  |
| Acquisition-related and other |  143  |  |  —  |  |  897  |  |  —  |
| Bad debt |  40  |  |  36  |  |  54  |  |  1,855  |
| Total operating expenses |  10,428  |  |  11,561  |  |  30,865  |  |  25,113  |
|  |  |  |  |  |  |  |  |
| Income from operations |  5,736  |  |  6,620  |  |  17,280  |  |  25,660  |
|  |  |  |  |  |  |  |  |
| Interest and other (expense) income: |  |  |  |  |  |  |  |
| Interest expense |  (518)  |  |  (300)  |  |  (1,271)  |  |  (2,077)  |
| Interest income |  239  |  |  26  |  |  720  |  |  96  |
| Other (expense) income, net |  (251)  |  |  (214)  |  |  24  |  |  (631)  |
| Total interest and other expense |  (530)  |  |  (488)  |  |  (527)  |  |  (2,612)  |
|  |  |  |  |  |  |  |  |
| Income before income taxes |  5,206  |  |  6,132  |  |  16,753  |  |  23,048  |
| Provision for income taxes |  2,484  |  |  4,009  |  |  7,894  |  |  9,026  |
|  |  |  |  |  |  |  |  |
| Net income |  2,722  |  |  2,123  |  |  8,859  |  |  14,022  |
| Less: Net income attributable to noncontrolling interests |  16  |  |  103  |  |  142  |  |  289  |
| Net income attributable to common stockholders | $ 2,706  |  | $ 2,020  |  | $ 8,717  |  | $ 13,733  |
|  |  |  |  |  |  |  |  |
| Net income per share attributable to common stockholders: |  |  |  |  |  |  |  |
| Basic | $ 0.01  |  | $ 0.01  |  | $ 0.03  |  | $ 0.04  |
| Diluted | $ 0.01  |  | $ 0.01  |  | $ 0.02  |  | $ 0.04  |
|  |  |  |  |  |  |  |  |
| Weighted average common shares outstanding: |   |  |   |  |   |  |   |
| Basic |  339,025  |  |  329,454  |  |  337,111  |  |  324,340  |
| Diluted |  381,071  |  |  378,934  |  |  379,868  |  |  370,204  |

MariMed Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

|  | Nine months ended |
| --- | --- |
|  | September 30, |
|  | 2022 |  | 2021 |
| Cash flows from operating activities: |  |  |  |
| Net income attributable to common stockholders | $ 8,717  |  | $ 13,733  |
| Net income attributable to noncontrolling interests |  142  |  |  289  |
| Adjustments to reconcile net income to cash provided by operating activities: |  |  |  |
| Depreciation and amortization of property and equipment |  2,469  |  |  1,499  |
| Amortization of intangible assets |  854  |  |  518  |
| Stock-based compensation |  6,396  |  |  7,152  |
| Amortization of standalone warrant issuances |  —  |  |  776  |
| Amortization of warrants attached to debt |  —  |  |  539  |
| Amortization of beneficial conversion feature |  —  |  |  177  |
| Amortization of original issue discount |  —  |  |  52  |
| Bad debt expense |  54  |  |  1,855  |
| Obligations settled with common stock |  637  |  |  375  |
| Loss on obligations settled with equity |  —  |  |  3  |
| Gain on sale of investment |  —  |  |  (309) |
| Loss on changes in fair value of investments |  930  |  |  937  |
| Other investment income |  (954) |  |  —  |
| Changes in operating assets and liabilities: |  |  |  |
| Accounts receivable, net |  (4,856) |  |  (3,886) |
| Deferred rents receivable |  111  |  |  192  |
| Inventory |  (4,215) |  |  (4,163) |
| Other current assets |  (1,973) |  |  (1,641) |
| Other assets |  (113) |  |  (17) |
| Accounts payable |  2,372  |  |  2,098  |
| Accrued expenses and other |  (193) |  |  8,069  |
| Income taxes payable |  (4,804) |  |  —  |
| Net cash provided by operating activities |  5,574  |  |  28,248  |
|  |   |  |   |
| Cash flows from investing activities: |  |  |  |
| Purchases of property and equipment |  (9,985) |  |  (14,649) |
| Business acquisitions, net of cash acquired |  (12,746) |  |  —  |
| Advances toward future business acquisitions |  (800) |  |  —  |
| Purchases of cannabis licenses |  (330) |  |  (638) |
| Proceeds from sale of investment |  —  |  |  1,475  |
| Proceeds from notes receivable |  130  |  |  407  |
| Net cash used in investing activities |  (23,731) |  |  (13,405) |
|   |   |  |   |
| Cash flows from financing activities: |  |  |  |
| Proceeds from issuance of preferred stock |  —  |  |  23,000  |
| Equity issuance costs |  —  |  |  (387) |
| Proceeds from issuance of promissory notes |  —  |  |  35  |
| Principal payments of mortgages and promissory notes |  (1,033) |  |  (16,248) |
| Proceeds from mortgages |  3,000  |  |  2,700  |
| Proceeds from exercise of stock options |  10  |  |  31  |
| Proceeds from exercise of warrants |  —  |  |  93  |
| Repayment of loans from related parties |  —  |  |  (1,158) |
| Principal payments of finance leases |  (166) |  |  (26) |
| Redemption of minority interests |  (2,000) |  |  —  |
| Distributions |  (224) |  |  (301) |
| Net cash (used in) provided by financing activities |  (413) |  |  7,739  |
|  |   |  |   |
| Net (decrease) increase in cash and cash equivalents |  (18,570) |  |  22,582  |
| Cash and equivalents, beginning of year |  29,683  |  |  2,999  |
| Cash and cash equivalents, end of period | $ 11,113  |  | $ 25,581  |

MariMed Inc.

Reconciliation of Non-GAAP and GAAP Financial Measures

(in thousands, except percentages)

(unaudited)

|  |  |  |  |
| --- | --- | --- | --- |
|   | Three months ended |  | Nine months ended |
|  | September 30, |  | September 30, |
|   | 2022 |  | 2021 |  | 2022 |  | 2021 |
| **Non-GAAP Adjusted EBITDA** |   |  |   |  |   |  |   |
| ***GAAP Net income*** | $ 2,722  |  | $ 2,123  |  | $ 8,859  |  | $ 14,022  |
| Interest expense, net |  279  |  |  274  |  |  551  |  |  1,981  |
| Income tax provision |  2,484  |  |  4,009  |  |  7,894  |  |  9,026  |
| Depreciation and amortization of property and equipment |  917  |  |  536  |  |  2,469  |  |  1,499  |
| Amortization of acquired intangible assets |  429  |  |  172  |  |  854  |  |  518  |
| ***EBITDA (earnings before interest, taxes, depreciation and amortization)*** |  6,831  |  |  7,114  |  |  20,627  |  |  27,046  |
| Stock-based compensation |  1,372  |  |  5,552  |  |  6,396  |  |  7,152  |
| Settlement of litigation |  —  |  |  (266)  |  |  —  |  |  (266)  |
| Acquisition-related and other |  143  |  |  —  |  |  897  |  |  —  |
| Other expense (income), net |  251  |  |  214  |  |  (24)  |  |  631  |
| ***Adjusted EBITDA*** | $ 8,597  |  | $ 12,614  |  | $ 27,896  |  | $ 34,563  |
|   |  |  |  |  |  |  |  |
| **Non-GAAP Adjusted EBITDA Margin (Non-GAAP adjusted EBITDA as a percentage of revenue)** |  |  |  |  |  |  |  |
| ***GAAP Net income*** |  8.0%  |  |  6.4%  |  |  9.0%  |  |  15.5%  |
| Interest expense, net |  0.8%  |  |  0.8%  |  |  0.6%  |  |  2.2%  |
| Income tax provision |  7.3%  |  |  12.1%  |  |  8.0%  |  |  9.9%  |
| Depreciation and amortization of property and equipment |  2.7%  |  |  1.6%  |  |  2.5%  |  |  1.7%  |
| Amortization of acquired intangible assets |  1.3%  |  |  0.5%  |  |  0.9%  |  |  0.6%  |
| ***EBITDA margin*** |  20.1%  |  |  21.4%  |  |  21.0%  |  |  29.9%  |
| Stock-based compensation |  4.1%  |  |  16.8%  |  |  6.5%  |  |  7.9%  |
| Settlement of litigation |  —%  |  |  (0.8%) |  |  0.9%  |  |  (0.3%) |
| Acquisition-related and other |  0.4%  |  |  —%  |  |  —%  |  |  —%  |
| Other expense (income), net |  0.8%  |  |  0.6%  |  |  —%  |  |  0.7%  |
| ***Adjusted EBITDA margin*** |  25.4%  |  |  38.0%  |  |  28.4%  |  |  38.2%  |

MariMed Inc.

Supplemental Information

Revenue Components

(in thousands)

(unaudited)

|  |  |  |  |
| --- | --- | --- | --- |
|  | Three months ended |  | Nine months ended |
|  | September 30, |  | September 30, |
|  | 2022 |  | 2021 |  | 2022 |  | 2021 |
| Product revenue: |  |  |  |  |  |  |  |
| Product revenue - retail |  23,593  |  |  23,454  |  |  68,121  |  |  59,230  |
| Product revenue - wholesale |  9,009  |  |  6,633  |  |  23,029  |  |  20,536  |
| Total product revenue |  32,602  |  |  30,087  |  |  91,150  |  |  79,766  |
| Other revenue |  1,310  |  |  3,121  |  |  7,030  |  |  10,654  |
| Total revenue | $ 33,912  |  | $ 33,208  |  | $ 98,180  |  | $ 90,420  |